

DAFTAR PUSTAKA

- Ahmad, O. B., Boschi-Pinto, C., Lopez, A. D., Murray, C. J., Lozano, R., & Inoue, M. (2001). Age standardization of rates: a new WHO standard. GPE Discussion Paper Series: No31. Geneva: *World Health Organization*, 31, 1–14. <http://www.who.int/healthinfo/paper31.pdf>
- Arnedo-Pena, A. *et al.* (2020) "Atopic dermatitis incidence and risk factors in young adults in Castellon (Spain): A prospective cohort study," *Allergologia et Immunopathologia*, 48(6), hal. 694–700. doi: 10.1016/j.aller.2020.01.004.
- Bagnasco, D. *et al.* (2016) "A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma," *International Archives of Allergy and Immunology*, 170(2), hal. 122–131. doi: 10.1159/000447692.
- Canavan, T. N. *et al.* (2016) "Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review," *American Journal of Clinical Dermatology*, 17(1), hal. 33–47. doi: 10.1007/s40257-015-0162-4.
- Cesare, A. Di, Meglio, P. Di dan Nestle, F. O. (2008) "A role for Th17 cells in the immunopathogenesis of atopic dermatitis?," *Journal of Investigative Dermatology*, 128(11), hal. 2569–2571. doi: 10.1038/jid.2008.283.
- Chovatiya, R. (2020) "Atopic dermatitis," *The Lancet*, 396(10247), hal. 345–360. doi: 10.1016/S0140-6736(20)31286-1.
- Dewi, N. W. S. *et al.* (2017) "Ethanol extract of the powder of red earthworm (*Lumbricus rubellus*) obtained from several organic farmlands in Bali, Indonesia: Analysis of total phenolic content and antioxidant capacity," *Bali Medical Journal*, 6(3), hal. 80. doi: 10.15562/bmj.v6i3.730.
- Doğruel, D. *et al.* (2016) "Prevalence of and risk factors for atopic dermatitis: A birth cohort study of infants in southeast Turkey," *Allergologia et Immunopathologia*, 44(3), hal. 214–220. doi: 10.1016/j.aller.2015.07.002.
- Eyerich, K. *et al.* (2009) "IL-17 in atopic eczema: Linking allergen-specific adaptive and microbial-triggered innate immune response," *Journal of Allergy and Clinical Immunology*, 123(1), hal. 59–66.e4. doi: 10.1016/j.jaci.2008.10.031.
- Foekh, N. P., Sukrama, I. D. M. dan Lestari, A. A. W. (2019) "The ability of earthworm *Lumbricus rubellus* extract in slowing down the activation of NFκB and TNF-Î± in lipopolysaccharide-induced *Rattus norvegicus*," *Bali Medical Journal*, 8(2), hal. 439–444. doi: 10.15562/bmj.v8i2.1405.
- Gaffen, S.L. (2008) 'An Overview of IL-17 Function and Signaling', *Occup Environ Med*, 23(1), pp. 1–7. Available at: <https://doi.org/10.1016/j.cyto.2008.07.017>.An.
- Kapur, S., Watson, W. dan Carr, S. (2018) "Atopic dermatitis," *Allergy, Asthma and Clinical Immunology*, 14(s2), hal. 1–10. doi: 10.1186/s13223-018-0281-6.
- Kim, J., Kim, B. E. dan Leung, D. Y. M. (2019) "Pathophysiology of atopic dermatitis: Clinical implications," *Allergy and Asthma Proceedings*, 40(2), hal. 84–92. doi: 10.2500/aap.2019.40.4202.
- Krzysiek, J. *et al.* (2022) "The role of heterodimer IL-17-A/F in atopic dermatitis," *Postepy Dermatologii i Alergologii*, 39(6), hal. 1093–1100. doi: 10.5114/ada.2022.122604.
- Liu, T. *et al.* (2020) "The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside," *Frontiers in Immunology*, 11(November), hal. 1–13. doi: 10.3389/fimmu.2020.594735.
- Luger, T. *et al.* (2021) "Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents," *Journal of Dermatological Science*, 102(3), hal. 142–157. doi: 10.1016/j.jdermsci.2021.04.007.
- McGeachy, M. J., Cua, D. J. dan Gaffen, S. L. (2019) "The IL-17 Family of Cytokines in Health and Disease," *Immunity*, 50(4), hal. 892–906. doi: 10.1016/j.immuni.2019.03.021.
- Niebuhr, M. *et al.* (2011) 'Staphylococcal alpha-toxin is a strong inducer of interleukin-17 in humans', *Infection and Immunity*, 79(4), pp. 1615–1622. Available at: <https://doi.org/10.1128/IAI.00958-10>.
- Ng, Y. T. dan Chew, F. T. (2020) "A systematic review and meta-analysis of risk factors associated with atopic dermatitis in Asia," *World Allergy Organization Journal*, 13(11), hal. 100477. doi: 10.1016/j.waojou.2020.100477.
- Peng, W. dan Novak, N. (2015) "Pathogenesis of atopic dermatitis," *Clinical and Experimental Allergy*, 45(3), hal. 566–574. doi: 10.1111/cea.12495.
- Pyun, B. Y. (2014) "Natural history and risk factors of atopic dermatitis in children," *Allergy, Asthma and Immunology Research*, 7(2), hal. 101–105. doi: 10.4168/aair.2015.7.2.101.

- Sharma, S. *et al.* (2019) "How to calculate sample size for observational and experiential nursing research studies?," *National Journal of Physiology, Pharmacy and Pharmacology*, 10(0), hal. 1. doi: 10.5455/njppp.2020.10.0930717102019.
- Tabri, F. *et al.* (2021) "The effectiveness of lumbricus rubellus extract toward interleukin-10 and immunoglobulin e and atopic dermatitis scoring index (SCORAD)," *Open Access Macedonian Journal of Medical Sciences*, 9, hal. 1428–1434. doi: 10.3889/oamjms.2021.7196.
- Taleb, S., Tedgui, A. dan Mallat, Z. (2015) "IL-17 and Th17 cells in atherosclerosis: Subtle and contextual roles," *Arteriosclerosis, Thrombosis, and Vascular Biology*, 35(2), hal. 258–264. doi: 10.1161/ATVBAHA.114.303567.
- Tan, Q. *et al.* (2017) "Establishing a role for interleukin-17 in atopic dermatitis-related skin inflammation," *Journal of Cutaneous Medicine and Surgery*, 21(4), hal. 308–315. doi: 10.1177/1203475417697651.
- Trisina, J. *et al.* (2011) "DLBS1033, a protein extract from lumbricus rubellus, possesses antithrombotic and thrombolytic activities," *Journal of Biomedicine and Biotechnology*, 2011. doi: 10.1155/2011/519652.
- Ungar, B. *et al.* (2021) "Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis," *Journal of Allergy and Clinical Immunology*, 147(1), hal. 394–397. doi: 10.1016/j.jaci.2020.04.055.
- Yao, X. *et al.* (2021) "Guidelines for Diagnosis and Treatment of Atopic Dermatitis in China (2020)," *International Journal of Dermatology and Venereology*, 4(1), hal. 1–9. doi: 10.1097/JD9.0000000000000143.
- Hofmann MA, Fluhr JW, Ruwwe-Glösenkamp C, Stevanovic K, Bergmann KC, Zuberbier T. Role of IL-17 in atopy—A systematic review. *Clin Transl Allergy*. 2021 Aug 1;11(6):1–7.
- Hayashida S, Uchi H, Moroi Y, Furue M. Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. *J Dermatol Sci*. 2011 Mar;61(3):180–6.
- Zhang, Q. *et al.* (2019) "The complete mitochondrial genome of Lumbricus rubellus (Oligochaeta, Lumbricidae) and its phylogenetic analysis," *Mitochondrial DNA Part B: Resources*, 4(2), hal. 2677–2678. doi: 10.1080/23802359.2019.1644242.
- Mack, M.C., Chu, M.R., Tierney, N.K., Ruvolo Jr, E., Stamatas, G.N., Kollias, N., Bhagat, K., Ma, L. and Martin, K.M., 2016. Water-holding and transport properties of skin stratum corneum of infants and toddlers are different from those of adults: studies in three geographical regions and four ethnic groups. *Pediatric Dermatology*, 33(3), pp.275-282.
- Maizels, R.M. and McSorley, H.J., 2016. Regulation of the host immune system by helminth parasites. *Journal of Allergy and Clinical Immunology*, 138(3), pp.666-675.
- Sitcharungsi, R. and Sirivichayakul, C., 2013. Allergic diseases and helminth infections. *Pathogens and global health*, 107(3), pp.110-115.

LAMPIRAN

Lampiran 1. Pengajuan Persetujuan Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agusselim Buhari, MMed, PhD, SpCK, TSP, 081241850658, 0411 5780603, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 618/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 14 Agustus 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24070530	No Sponsor	
Peneliti Utama	dr. Andi Putri Suci Ramadhani	Sponsor	
Judul Peneliti	Pengaruh Ekstrak Lumbricus Rubellus terhadap Interleukin-17 pada Penderita Dermatitis Atopik		
No Versi Protokol	2	Tanggal Versi	14 Agustus 2024
No Versi PSP	2	Tanggal Versi	14 Agustus 2024
Tempat Penelitian	RS Universitas Hasanuddin dan RSUP, Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 14 Agustus 2024 sampai 14 Agustus 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian risiko tinggi dan setiap setahun untuk penelitian risiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. *Informed Consent*



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10, Makassar
90245

Contact Person: dr. Agus Salim Bukhari, MMed, PhD, SpGK, email: agussalim@yahoo.com Fax: 0411-581431



Lampiran 2.

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN

Saya yang bertanda tangan di bawah ini :

Nama :

Umur :

Alamat :

Setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan dan manfaat apa yang akan dilakukan pada penelitian ini, maka saya menyatakan setuju untuk ikut dalam penelitian ini.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Juga saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini akan ditanggung oleh peneliti. Adapun biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akibat penelitian ini akan dibiayai oleh peneliti.

Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan dengan ini saya menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Bila terjadi perbedaan pendapat dikemudian hari kami akan menyelesaikannya secara kekeluargaan.

NAMA	<u>HUBUNGAN</u>	TANDA TANGAN	TGL/BLN/THN
	<u>DENGAN SUBJEK</u>		
Klien			
Saksi 1			
Saksi 2			

Penanggung Jawab Penelitian	Penanggung Jawab Medis
Nama : dr. Andi Putri Suci Ramadhani	Nama: Prof. Dr. dr. Farida Tabri,Sp.DVE(K)FINS DV,
Alamat : Perumahan dosen unhas tamalanrea	FAADV
blok GB No. 37	Alamat: Perumahan Graha Satelit Blok I No.21
Telepon : 08114499009	Telepon: 08124208996

Lampiran 3. Data Penelitian**Kelompok Kontrol**

No.	Nama	Umur	Kode Lab	Kadal IL-17	
				Minggu 0	Minggu 4
1	Ayu	35	FK1	29.82345345	27.97654566
2	Iqra	39	FK2	28.00457856	28.57346366
3	Yahfiz	19	FK3	26.89764576	25.73346885
4	dr. Andi Hardianty	36	FK4	31.20645767	29.24436775
5	Hafiz	12	FK5	33.34345385	28.27432354
6	Airlangga	14	FK6	25.11346393	29.32567584
7	Marlia	45	FK7	26.75345344	21.29456549
8	Keyla	11	FK8	29.24346365	26.35363546
9	Arif	13	FK9	29.48364536	25.73123489
10	Kenis	8	FK10	27.05353463	25.29345325
11	Masyita	17	FK11	30.72436346	24.06345339
12	Naila	13	FK12	32.27658558	32.66234785
13	Inayah	9	FK13	33.81568556	33.35346547
14	Nur Ernawati	21	FK14	30.61575675	25.77546646
15	April	13	FK15	28.28234789	26.89457434
16	Sinta	28	FK16	31.67695943	29.56454689
17	Akbar	17	FK17	37.47346833	25.10454368
18	Raisa	2	FK18	29.32567584	27.49545198
19	Rahma	14	FK19	21.29456549	20.76543422
20	Abd. Rahman	15	FK20	36.35363546	31.90353456
21	Hera	21	FK21	17.73123489	17.47324355
22	Hajir	23	FK22	25.29345325	24.75278696

No.	Nama	Umur	Kode Lab	SCORAD	
				Minggu 0	Minggu 4
1	Ayu	35	FK1	54	49
2	Iqra	39	FK2	49	43
3	Yahfiz	19	FK3	53	48
4	dr. Andi Hardianty	36	FK4	46	42
5	Hafiz	12	FK5	32	29
6	Airlangga	14	FK6	30	27
7	Marlia	45	FK7	29	24
8	Keyla	11	FK8	23	19
9	Arif	13	FK9	19	18
10	Kenis	8	FK10	17	16
11	Masyita	17	FK11	15	14
12	Naila	13	FK12	44	41
13	Inayah	9	FK13	37	33
14	Nur Ernawati	21	FK14	31	27
15	April	13	FK15	28	25
16	Sinta	28	FK16	25	22
17	Akbar	17	FK17	21	18
18	Raisa	2	FK18	47	42
19	Rahma	14	FK19	36	34
20	Abd. Rahman	15	FK20	43	39
21	Hera	21	FK21	28	26
22	Hajir	23	FK22	51	32
Jumlah				758	668
Rata-rata				34,45	30,36
Min				15	14
Max				54	49

Kelompok Perlakuan

No.	Nama	Umur	Kode Lab	Kadar IL-17	
				Minggu 0	Minggu 4
1	Sheila	9	F.1	34.32278696	24.38435891
2	Doa	8	F.2	28.94546646	18.07241489
3	Dewi	18	F.3	24.92546771	12.92152153
4	Ny. Monika	55	F.4	31.83556481	15.58178975
5	Arnain	16	F.5	34.57123289	28.33345639
6	Juliani	28	F.6	32.40324376	19.58346432
7	Fadhil	21	F.7	33.81234389	24.39346347
8	Salsa	15	F.8	28.19323432	23.25348794
9	Siti	17	F.9	29.82453893	27.86325298
10	Apriadi	18	F.10	27.97334678	24.14346378
11	Saskia	13	F.11	29.84345649	26.24347897
12	Laode	13	F.12	33.12565898	22.06457869
13	Dumani	14	F.13	27.64898234	12.72478468
14	A. M. Nova	13	F.14	33.06332569	22.76679544
15	Alifa	10	F.15	29.59343569	24.41457986
16	Ainun	13	F.16	22.22431218	17.30457898
17	Hisran	8	F.17	34.78544891	13.91678543
18	Aisyah	8	F.18	30.72436346	20.01457679
19	Rafa	13	F.19	37.27658558	32.40235246
20	Feby	8	F.20	33.81568556	29.79346381
21	Rasikul	13	F.21	30.61575675	17.78342355
22	A. Rayhan	13	F.22	32.28234789	35.93235298

No.	Nama	Umur	Kode Lab	SCORAD	
				Minggu 0	Minggu 4
1	Sheila	9	F.1	54	21
2	Doa	8	F.2	49	28
3	Dewi	18	F.3	53	31
4	Ny. Monika	55	F.4	46	24
5	Arnain	16	F.5	32	17
6	Juliani	28	F.6	30	18
7	Fadhil	21	F.7	29	16
8	Salsa	15	F.8	23	14
9	Siti	17	F.9	19	13
10	Apriadi	18	F.10	21	15
11	Saskia	13	F.11	34	10
12	Laode	13	F.12	44	23
13	Dumani	14	F.13	37	19
14	A. M. Nova	13	F.14	31	22
15	Alifa	10	F.15	28	14
16	Ainun	13	F.16	25	12
17	Hisran	8	F.17	21	15
18	Aisyah	8	F.18	26	12
19	Rafa	13	F.19	37	11
20	Feby	8	F.20	46	23
21	Rasikul	13	F.21	35	13
22	A. Rayhan	13	F.22	42	19
Jumlah				762	390
Rata-rata				34,64	17,73
Min				19	10
Max				54	31

Lampiran 4. Hasil Pengolahan Data

Uji Normalitas :

Case Processing Summary

	Minggu	Valid		Cases Missing		Total	
		N	Percent	N	Percent	N	Percent
Kolompok Kontrol	Minggu 0	22	100.0%	0	0.0%	22	100.0%
	Mingggu 4	22	100.0%	0	0.0%	22	100.0%
Kelompok Perlakaun	Minggu 0	22	100.0%	0	0.0%	22	100.0%
	Mingggu 4	22	100.0%	0	0.0%	22	100.0%

Tests of Normality

	Minggu	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Kolompok Kontrol	Minggu 0	.114	22	.200*	.968	22	.671
	Mingggu 4	.122	22	.200*	.967	22	.648
Kelompok Perlakaun	Minggu 0	.098	22	.200*	.965	22	.600
	Mingggu 4	.104	22	.200*	.975	22	.813

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Uji Independen T Test II-17

Group Statistics

	Minggu	N	Mean	Std. Deviation	Std. Error Mean
Kolompok Kontrol	Minggu 0	22	29.1721	4.50754	.96101
	Mingggu 4	22	26.7095	3.80751	.81176
Kelompok Perlakaun	Minggu 0	22	30.9912	3.50351	.74695
	Mingggu 4	22	22.4497	6.23020	1.32828

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
Kolompok Kontrol	Equal variances assumed	.264	.610	1.958	42	.057	2.46260	1.25798	-.07609	5.00130
	Equal variances not assumed			1.958	40.858	.057	2.46260	1.25798	-.07820	5.00341
Kelompok Perlakaun	Equal variances assumed	6.106	.018	5.605	42	.000	8.54155	1.52390	5.46620	11.61691
	Equal variances not assumed			5.605	33.074	.000	8.54155	1.52390	5.44142	11.64169

Paired Sampel T Test II-17

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	Minggu 0 Kontrol	29.1721	22	4.50754	.96101
	Minggu 4 Kontrol	26.7095	22	3.80751	.81176
Pair 2	Minggu 0 Perlakuan	30.9912	22	3.50351	.74695
	Minggu 4 Perlakuan	22.4497	22	6.23020	1.32828

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	Minggu 0 Kontrol & Minggu 4 Kontrol	22	.701	.000
Pair 2	Minggu 0 Perlakuan & Minggu 4 Perlakuan	22	.474	.026

Paired Samples Test

		Paired Differences							
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference		t	df	Sig. (2-tailed)
					Lower	Upper			
Pair 1	Minggu 0 Kontrol - Minggu 4 Kontrol	2.46260	3.27777	.69882	1.00932	3.91589	3.524	21	.102
Pair 2	Minggu 0 Perlakuan - Minggu 4 Perlakuan	8.54155	5.51316	1.17541	6.09715	10.98595	7.267	21	.000

Uji Normalitas Scord

Case Processing Summary

		Valid		Cases Missing		Total	
		N	Percent	N	Percent	N	Percent
SCORAD KONTROL	Minggu 0	22	100.0%	0	0.0%	22	100.0%
	Minggu 4	22	100.0%	0	0.0%	22	100.0%
SCORAD PERLAKUAN	Minggu 0	22	100.0%	0	0.0%	22	100.0%
	Minggu 4	22	100.0%	0	0.0%	22	100.0%

Tests of Normality

		Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
SCORAD KONTROL	Minggu 0	.125	22	.200*	.946	22	.260
	Minggu 4	.125	22	.200*	.942	22	.220
SCORAD PERLAKUAN	Minggu 0	.098	22	.200*	.952	22	.341
	Minggu 4	.140	22	.200*	.940	22	.202

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Uji Independen T Test Scorad

Group Statistics

	Minggu	N	Mean	Std. Deviation	Std. Error Mean
SCORAD KONTROL	Minggu 0	22	34.4545	12.24639	2.61094
	Minggu 4	22	29.1364	10.57983	2.25563
SCORAD PERLAKUAN	Minggu 0	22	34.6364	10.61690	2.26353
	Minggu 4	22	17.7273	5.64996	1.20458

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
SCORAD KONTROL	Equal variances assumed	.981	.328	1.541	42	.131	5.31818	3.45034	-1.64489	12.28125
	Equal variances not assumed			1.541	41.132	.131	5.31818	3.45034	-1.64924	12.28561
SCORAD PERLAKUAN	Equal variances assumed	9.232	.004	6.595	42	.000	16.90909	2.56409	11.73454	22.08364
	Equal variances not assumed			6.595	32.011	.000	16.90909	2.56409	11.68628	22.13191

Paired Sampel T Test Scorad

Paired Samples Statistics

		Mean	N	Std. Deviation	Std. Error Mean
Pair 1	SCORAD M0 KONTROL	34.4545	22	12.24639	2.61094
	SCORAD M4 KONTROL	30.3636	22	10.67059	2.27498
Pair 2	SCORAD M0 PERLAKUAN	34.6364	22	10.61690	2.26353
	SCORAD M4 PERLAKUAN	17.7273	22	5.64996	1.20458

Paired Samples Correlations

		N	Correlation	Sig.
Pair 1	SCORAD M0 KONTROL & SCORAD M4 KONTROL	22	.960	.000
Pair 2	SCORAD M0 PERLAKUAN & SCORAD M4 PERLAKUAN	22	.755	.000

		Paired Samples Test							
		Paired Differences							
		Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference		t	df	Sig. (2-tailed)
					Lower	Upper			
Pair 1	SCORAD M0 KONTROL - SCORAD M4 KONTROL	4.09091	3.61095	.76986	2.48990	5.69191	5.314	21	.000
Pair 2	SCORAD M0 PERLAKUAN - SCORAD M4 PERLAKUAN	16.90909	7.35436	1.56795	13.64835	20.16983	10.784	21	.000

Lampiran 5. Dokumentasi Penelitian

Pengambilan sampel, Pemeriksaan Elisa Interleukin-17

